Yang Hua-Qiang, Zhang Rong-Huan, Zhang Zheng-Hua, Wan Chu-Cheng, Xia Yun-Jin
Department of Hemotology, Taihe Hospital, Yunyang Medical College, Shiyan, Hubei, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2007 Dec;9(6):526-8.
To detect plasma concentrations of vascular endothelial cell growth factor (VEGF) and tissue factor (TF) in children with acute lymphoblastic leukemia (ALL) and explore their clinical significance in ALL.
Thirty-three children with newly diagnosed ALL, including 18 cases of low risk, 7 cases of moderate risk and 8 cases of high risk, were enrolled in this study. Twenty-five patients received a complete remission and 8 cases were in non-remission after conventional remission induction chemotherapy. Plasma concentrations of VEGF and TF in the patients were detected using ELISA before and after treatment. Sixteen healthy children served as normal control group.
Plasma concentrations of VEGF and TF in ALL patients before treatment were significantly higher than those in normal controls (P < 0.01). Plasma concentrations of VEGF and TF in the non-remission group before treatment were significantly higher than those in the remission group (P < 0.05) and the control group (P < 0.01). After treatment the plasma concentrations of VEGF and TF in the non-remission group were not significantly reduced and higher than those in the remission and the control groups (P < 0.01). There were significant differences in plasma concentrations of VEGF and TF among the low-risk, moderate-risk and high-risk groups before and after treatment (P < 0.05). Plasma concentrations of VEGF and TF in the high risk group were not significantly reduced after treatment and higher than those in the control group (P < 0.01). A linear correlation was noted between plasma VEGF and TF concentrations in ALL patients before treatment (r=0.50, P < 0.01).
VEGF and TF play an important role in the development of ALL and may be useful to the evaluation of the severity and the outcome in ALL.
检测急性淋巴细胞白血病(ALL)患儿血浆血管内皮生长因子(VEGF)和组织因子(TF)浓度,探讨其在ALL中的临床意义。
选取33例新诊断的ALL患儿,其中低危18例、中危7例、高危8例。25例经传统诱导缓解化疗后完全缓解,8例未缓解。采用酶联免疫吸附测定法(ELISA)检测患儿治疗前后血浆VEGF和TF浓度。选取16例健康儿童作为正常对照组。
ALL患儿治疗前血浆VEGF和TF浓度显著高于正常对照组(P<0.01)。未缓解组治疗前血浆VEGF和TF浓度显著高于缓解组(P<0.05)及对照组(P<0.01)。治疗后,未缓解组血浆VEGF和TF浓度未显著降低,且高于缓解组及对照组(P<0.01)。治疗前后,低危、中危和高危组患儿血浆VEGF和TF浓度差异有统计学意义(P<0.05)。高危组治疗后血浆VEGF和TF浓度未显著降低,且高于对照组(P<0.01)。ALL患儿治疗前血浆VEGF与TF浓度呈线性相关(r=0.50, P<0.01)。
VEGF和TF在ALL发生发展中起重要作用,可能有助于评估ALL的严重程度及预后。